Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MB-dNPM1-TCR.1 by Miltenyi Biomedicine for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
MB-dNPM1-TCR.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...